GEN Edge StockWatch: Investors Warm to Moderna’s COVID-19 Sales, Vaccine Updates

Moderna’s flurry of updates from its Vaccine Day scored well enough with investors as shares rose 6% on Tuesday. The SpikeVax developer raised its 2022 sales forecast for the COVID-19 vaccine by 10.5%, from $19 billion to $21 billion, citing Japan’s purchase of 70 million more doses plus the expectation of a sales jump as SARS-CoV-2 becomes endemic by fall/winter . . .

The post GEN Edge StockWatch: Investors Warm to Moderna’s COVID-19 Sales, Vaccine Updates appeared first on GEN – Genetic Engineering and Biotechnology News.

Source